Roche Blocks Indian Trastuzumab; Says No Room For ''Uncertainty''
This article was originally published in Scrip
Executive Summary
Roche has moved to block Reliance Life Sciences Pvt Ltd's biosimilar version of its anticancer Herceptin (trastuzumab) in India citing "genuine" concern over the comparable safety and efficacy of the Indian firm's product.
You may also be interested in...
Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs
An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).
Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs
An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.